TrialInvestigational new drugs2022

First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.

Jordan Berlin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.